According to the CDC, those who got a second booster were seven times less likely to be hospitalized -- and 21 times less likely to die from COVID-19 -- than the unvaccinated. But in real numbers, the risk -- even for the elderly -- is much smaller to begin with if ...
“It is disappointing that healthcare providers are unable to add the power of a mAb therapy for treatment of COVID-19 to our current therapeutic options. Current treatments such as PAXLOVID® may be contraindicated, clinically inappropriate, or not accessible for patients, especially...
While PAXLOVID™ is still very effective for people who are unvaccinated or have significant co-morbidities (for example, obesity, hypertension, etc.), Pfizer’s failure to be upfront about a large percentage of the U.S. population who would not benefit from the drug is informative about t...
PaxlovidPrescriptions filledSymptom onset dateAlthough real-world studies demonstrate that those prescribed nirmatrelvir/ritonavir (and particularly within 5days of symptom onset) are less likely to experience severe COVID-19 outcomes, prior studies show that only a small fraction of patients with CO...
When it comes to COVID, people living in disadvantaged communities are hit with a triple whammy. First, they're more likely to get infected, and when sick, are more likely to have serious disease. Second, they're more likely to develop long COVID. Third,
Paxlovid also can't be taken alongside someother medicationssuch as those for certain heart conditions, mental health conditions and cancers. For high-risk patients in these cases, Lagevrio can be considered. Some people who take COVID antivirals will experience side effects. Mostly these are no...